至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Transmission Reducing and Enhancing Monoclonal Antibodies against Plasmodium vivax Gamete Surface Protein Pvs48/45

Infect Immun. 2024-03; 
Geetha P Bansal, Maisa da Silva Araujo, Yi Cao, Emily Shaffer, Jessica Evangelista Araujo, Jansen Fernandes Medeiros, Clifford Hayashi, Joseph Vinetz, Nirbhay Kumar
Products/Services Used Details Operation
Gene Synthesis Recombinant full-length Pvs48/45 (PlasmoDB accession number PVX_083235) was prepared as described (19). Briefly, the codon-harmonized sequence of Pvs48/45 (GenScript) was cloned between NdeI and NotI restriction sites of the expression vector pET(K-) modified to allow expression with an in-frame C-terminal 6× histidine tag. Get A Quote

摘要

Gamete surface protein P48/45 has been shown to be important for male gamete fertility and a strong candidate for the development of a malaria transmission-blocking vaccine (TBV). However, TBV development for Plasmodium vivax homolog Pvs48/45 has been slow because of a number of challenges: availability of conformationally suitable recombinant protein; the lack of an in vivo challenge model; and the inability to produce P. vivax gametocytes in culture to test transmission-blocking activity of antibodies. To support ongoing efforts to develop Pvs48/45 as a potential vaccine candidate, we initiated efforts to develop much needed reagents to move the field forward. We generated monoclonal antibodies (mAbs) directe... More

关键词

Anopheles darlingi; Plasmodium vivax; Pvs48/45; monoclonal antibodies; transmission-blocking vaccine; transmission-enhancing activity; transmission-reducing activity.